198
Participants
Start Date
July 8, 2021
Primary Completion Date
October 31, 2022
Study Completion Date
April 30, 2023
Olokizumab
Olokizumab, 128 mg, solution for subcutaneous administration 160 mg/mL
Standard therapy
"Standard treatment including:~* Baricitinib, 4 mg, film coated tablets~* Favipiravir, 200 mg, film coated tablets~* Dexamethasone IV or IM OR Methylprednisolone IV"
"State Budgetary Healthcare Institution City Clinical Hospital named after F.I. Inozemtsev of Moscow Healthcare Department", Moscow
"Federal State Budgetary Institution Central Clinical Hospital with a Polyclinic of Presidential Administration of the Russian Federation", Moscow
"State Budgetary Healthcare Institution City Clinical Hospital № 52 of Moscow Healthcare Department", Moscow
"State Budgetary Healthcare Institution Infectious Diseases Hospital No. 1 of Moscow Healthcare Department", Moscow
"State Budgetary healthcare Institution of the Voronezh region Voronezh Regional Clinical Hospital No. 1", Voronezh
Lead Sponsor
"Federal Budget Institution of Science Central Research Institute of Epidemiology of the Rospotrebnadzor"
UNKNOWN
Group of companies Medsi, JSС
UNKNOWN
R-Pharm
INDUSTRY